Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Aug;65(8):1087-95.
doi: 10.1016/j.metabol.2016.01.013. Epub 2016 Feb 2.

Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?

Naim Alkhouri  1 , Ariel E Feldstein  2
Affiliations
Review

Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?

Naim Alkhouri et al. Metabolism. 2016 Aug.

Abstract

Nonalcoholic fatty liver disease (NAFLD) has rapidly become the most common form of chronic liver disease in the United States affecting approximately 80-100 million Americans. NAFLD includes a spectrum of diseases ranging from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH) to fibrosis and eventually cirrhosis. Patients with NASH and significant fibrosis on liver biopsy have an increased risk for liver-related morbidity and mortality compared to those with NAFL. Due to the high prevalence of NAFLD and its progressive nature, there has been an urgent need to develop reliable noninvasive tests that can accurately predict the presence of advanced disease without the need for liver biopsy. These tests can be divided into those that predict the presence of NASH and those that predict the presence of fibrosis. In this review, we provide a concise overview of different noninvasive methods for staging the severity of NAFLD.

Keywords: Biomarkers; Fibrosis; NASH.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: AEF reports that he is named as co-inventor on pending and issued patents filed by the Cleveland Clinic and UCSD that refer to the use of biomarkers in fatty liver disorders. NA has no conflict of interest.

Figures

Figure 1
Figure 1. Different Imaging Studies for Liver Fibrosis in Patients with NAFLD
VCTE, Vibration controlled transient elastography; MRE, Magnetic resonance elastography; ARFI, Acoustic radiation force impulse.
Figure 2
Figure 2. Algorithm to Diagnose Advanced Fibrosis in NAFLD
The algorithm is based on using the combination of liver stiffness measurement (LSM) by vibration controlled transient elastography (VCTE) plus the NAFLD fibrosis score (NFS). Having concordant low values for both LSM and NFS indicates the absence of advanced fibrosis and both tests can be repeated in 2–3 years. Having concordant high values for both tests indicates the presence of advanced fibrosis and the need to screen for cirrhosis complications including hepatocellular carcinoma and varices. Having discordant results indicates the need for liver biopsy to determine the fibrosis stage.
See this image and copyright information in PMC

References

    1. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40(6):1387–95. - PubMed
    1. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006;118(4):1388–93. - PubMed
    1. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140(1):124–31. - PubMed
    1. Boza C, Riquelme A, Ibanez L, Duarte I, Norero E, Viviani P, et al. Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obes Surg. 2005;15(8):1148–53. doi: 10.1381/0960892055002347. - DOI - PubMed
    1. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Alimentary pharmacology & therapeutics. 2011;34(3):274–85. doi: 10.1111/j.1365-2036.2011.04724.x. - DOI - PubMed

MeSH terms